MX2016017407A - Inhibidores de histona demetilasa. - Google Patents

Inhibidores de histona demetilasa.

Info

Publication number
MX2016017407A
MX2016017407A MX2016017407A MX2016017407A MX2016017407A MX 2016017407 A MX2016017407 A MX 2016017407A MX 2016017407 A MX2016017407 A MX 2016017407A MX 2016017407 A MX2016017407 A MX 2016017407A MX 2016017407 A MX2016017407 A MX 2016017407A
Authority
MX
Mexico
Prior art keywords
cancer
compositions
compounds
histone demethylase
useful
Prior art date
Application number
MX2016017407A
Other languages
English (en)
Inventor
Brennan Wallace Michael
K Chen Young
Boloor Amogh
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2016017407A publication Critical patent/MX2016017407A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La presente descripción se relaciona generalmente a composiciones y métodos para tratar cáncer y enfermedad neoplásica. En la presente se proporcionan compuestos derivados de piridina sustituidos y composiciones farmacéuticas que comprenden los compuestos. Los presentes compuestos y composiciones son útiles para inhibición de histona demetilasa. Además, los presentes compuestos y composiciones son útiles para el tratamiento de cáncer, tales como cáncer de próstata, cáncer de seno, cáncer de vejiga, cáncer de pulmón y/o melanoma y los similares.
MX2016017407A 2014-06-25 2015-06-25 Inhibidores de histona demetilasa. MX2016017407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017201P 2014-06-25 2014-06-25
PCT/US2015/037812 WO2015200709A1 (en) 2014-06-25 2015-06-25 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
MX2016017407A true MX2016017407A (es) 2017-04-27

Family

ID=54929774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017407A MX2016017407A (es) 2014-06-25 2015-06-25 Inhibidores de histona demetilasa.

Country Status (29)

Country Link
US (7) US10385047B2 (es)
EP (3) EP3160952B1 (es)
JP (1) JP6521535B2 (es)
KR (1) KR102591897B1 (es)
CN (2) CN106660982B (es)
AR (1) AR100997A1 (es)
AU (1) AU2015279719B2 (es)
BR (1) BR112016030367A2 (es)
CA (1) CA2953437C (es)
CL (1) CL2016003301A1 (es)
CO (1) CO2017000359A2 (es)
CY (1) CY1123906T1 (es)
DK (1) DK3160952T3 (es)
EA (1) EA031200B1 (es)
EC (1) ECSP17004931A (es)
ES (1) ES2862648T3 (es)
HR (1) HRP20210299T1 (es)
HU (1) HUE053876T2 (es)
IL (1) IL249629A0 (es)
LT (1) LT3160952T (es)
MX (1) MX2016017407A (es)
NZ (1) NZ728120A (es)
PL (1) PL3160952T3 (es)
PT (1) PT3160952T (es)
SA (1) SA516380585B1 (es)
SG (1) SG11201610813TA (es)
SI (1) SI3160952T1 (es)
TW (2) TWI715533B (es)
WO (1) WO2015200709A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015014968A2 (pt) 2012-12-21 2017-07-11 Quanticel Pharmaceuticals Inc inibidores de histona-desmetilase
PL3160952T3 (pl) 2014-06-25 2021-07-19 Celgene Quanticel Research, Inc. Inhibitory metylazy histonowej
EA201790603A1 (ru) 2014-09-17 2017-10-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистондеметилазы
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10059687B2 (en) * 2015-12-28 2018-08-28 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
ES2921009T3 (es) * 2016-03-15 2022-08-16 Celgene Quanticel Res Inc Inhibidores de desmetilasas de histonas
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3600301A4 (en) * 2017-03-30 2020-08-12 Albert-Ludwigs-Universität Freiburg KDM4 INHIBITORS
CN109825551B (zh) * 2019-02-21 2022-08-02 深圳大学 一种评价组蛋白赖氨酸去甲基转移酶活性的方法
CN111679072B (zh) * 2020-06-15 2022-04-29 温州医科大学 Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用
WO2022217100A1 (en) * 2021-04-09 2022-10-13 Tachyon Therapeutics, Inc. Treatment of cancer with kdm4 inhibitors
CA3227684A1 (en) * 2021-08-18 2023-02-23 Jr. Richard M. Heid Process for preparing histone demethylase inhibitors
WO2023122221A1 (en) * 2021-12-23 2023-06-29 Tachyon Therapeutics, Inc. Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid
WO2023240253A2 (en) 2022-06-10 2023-12-14 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2023250480A1 (en) * 2022-06-23 2023-12-28 The Cleveland Clinic Foundation 3-βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
WO2024064734A1 (en) * 2022-09-21 2024-03-28 Celgene Corporation Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2- yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4- yl]methyl}amino)pyridine-4-carboxylic acid l-lysine salt, a histone demethylase inhibitor
CN115974647A (zh) * 2022-12-05 2023-04-18 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002397A (es) * 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
JP5554988B2 (ja) * 2006-04-07 2014-07-23 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7898712B2 (en) 2008-06-27 2011-03-01 Lockheed Martin Corporation Risley integrated steering module
GB201112607D0 (en) 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
JP6240063B2 (ja) 2011-04-28 2017-11-29 ザ ブロード インスティテュート, インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2013143597A1 (en) * 2012-03-29 2013-10-03 Glaxo Group Limited Demethylase enzymes inhibitors
WO2014089368A1 (en) 2012-12-05 2014-06-12 Bio-Rad Laboratories, Inc Methods for polymerase chain reaction copy number variation assays
JP6256771B2 (ja) 2012-12-06 2018-01-10 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
DK2934145T3 (en) * 2012-12-19 2018-02-05 Celgene Quanticel Res Inc HISTONDEMETHYLASE INHIBITORS
BR112015014968A2 (pt) 2012-12-21 2017-07-11 Quanticel Pharmaceuticals Inc inibidores de histona-desmetilase
PL3160952T3 (pl) 2014-06-25 2021-07-19 Celgene Quanticel Research, Inc. Inhibitory metylazy histonowej
EP3600301A4 (en) * 2017-03-30 2020-08-12 Albert-Ludwigs-Universität Freiburg KDM4 INHIBITORS

Also Published As

Publication number Publication date
US9994561B2 (en) 2018-06-12
KR102591897B1 (ko) 2023-10-19
CN106660982A (zh) 2017-05-10
CL2016003301A1 (es) 2021-03-05
HRP20210299T1 (hr) 2021-04-16
CN111909083A (zh) 2020-11-10
EA201692483A1 (ru) 2017-05-31
TWI715533B (zh) 2021-01-11
PT3160952T (pt) 2021-03-08
NZ728120A (en) 2023-06-30
BR112016030367A2 (pt) 2018-07-17
US10385047B2 (en) 2019-08-20
LT3160952T (lt) 2021-05-10
CN106660982B (zh) 2020-09-08
CO2017000359A2 (es) 2017-04-10
TW201613882A (en) 2016-04-16
AU2015279719B2 (en) 2019-03-21
SG11201610813TA (en) 2017-01-27
US20160107995A1 (en) 2016-04-21
CA2953437A1 (en) 2015-12-30
CY1123906T1 (el) 2022-05-27
US10106534B2 (en) 2018-10-23
ECSP17004931A (es) 2017-03-31
US9447046B2 (en) 2016-09-20
KR20170018079A (ko) 2017-02-15
IL249629A0 (en) 2017-02-28
US20180251458A1 (en) 2018-09-06
CN111909083B (zh) 2023-08-15
EP3160952A4 (en) 2018-02-21
SI3160952T1 (sl) 2021-07-30
US20150376169A1 (en) 2015-12-31
CA2953437C (en) 2022-08-30
AU2015279719A1 (en) 2017-02-02
PL3160952T3 (pl) 2021-07-19
US20170114055A1 (en) 2017-04-27
US9242968B2 (en) 2016-01-26
US20180044334A1 (en) 2018-02-15
US9586902B2 (en) 2017-03-07
US20160332970A1 (en) 2016-11-17
JP6521535B2 (ja) 2019-05-29
US20170158685A1 (en) 2017-06-08
US9815828B2 (en) 2017-11-14
TWI758004B (zh) 2022-03-11
TW202124369A (zh) 2021-07-01
HUE053876T2 (hu) 2021-07-28
ES2862648T3 (es) 2021-10-07
DK3160952T3 (da) 2021-03-08
EP3160952B1 (en) 2020-12-02
SA516380585B1 (ar) 2020-12-06
WO2015200709A1 (en) 2015-12-30
EP3160952A1 (en) 2017-05-03
AR100997A1 (es) 2016-11-16
EP3741749A1 (en) 2020-11-25
EP3738960A1 (en) 2020-11-18
JP2017523152A (ja) 2017-08-17
EA031200B1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
TW201613882A (en) Histone demethylase inhibitors
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX2017003464A (es) Inhibidores de histona desmetilasa.
MX2017003466A (es) Inhibidores de histona desmetilasa.
MX2016009663A (es) Derivados de icariina.
MX2017003463A (es) Inhibidores de histona desmetilasa.

Legal Events

Date Code Title Description
FG Grant or registration